In the Kaplan-Meier survival analysis for overall median (95% CI) survival of high pre-treatment coagulation parameters showed shorter PFS compared with normal pre-treatment except TT and their overall median (95% CI) follow-up was 3.3 (3.12-3.47). Univariate Cox regression and Multivariate Cox regression models were used to identify the factors that were associated with progression-free survival (PFS) and the response to palliative chemotherapy.
We find the clinical value of all these coagulation parameters by using SPSS 24. Blood samples were collected from these patients to measure the response levels of these coagulation parameters at time of admission to hospital and at the beginning of 4 cycles of Palliative therapy. A total of 216 advanced NSCLC patients who used a first-line chemotherapy and antiangiogenic therapy regimen were enrolled in this study under ethical approval (JSCH-2020C-009). Medical records of 5445 patients were succinctly reviewed and classified accordingly to the inclusion and exclusion criteria.
MethodsĪ retrospective study was conducted between 20 in Jiangsu Cancer hospital, Nanjing, PR. Study focuses to explore the clinical relevancy of Coagulation parameters prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (FIB), D-dimer and international normalised ratio (INR) and their response to palliative chemotherapy in advanced-stage NSCLC. Blood coagulation parameters are colossally important for clinical evaluation of palliative chemotherapy however, this niche was not explored earlier for advanced-stage non-small cell lung cancer (NSCLC).
0 kommentar(er)
